1
|
Lisowska M, Worrall EG, Zavadil-Kokas F, Charlton K, Murray E, Mohtar MA, Krejcir R, Hrabal V, Brydon J, Urionabarrenetxea AG, Saliba DG, Grima M, Kalathiya U, Muller P, Krejci A, Vojtesek B, Ball KL, Fahraeus R, Argyle DJ, Parys M, Hupp TR. The development of a canine single-chain phage antibody library to isolate recombinant antibodies for use in translational cancer research. CELL REPORTS METHODS 2025; 5:101008. [PMID: 40132540 PMCID: PMC12049728 DOI: 10.1016/j.crmeth.2025.101008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 07/10/2024] [Accepted: 02/25/2025] [Indexed: 03/27/2025]
Abstract
The development of canine immunotolerant monoclonal antibodies can accelerate the invention of new medicines for both canine and human diseases. We develop a methodology to clone the naive, somatically mutated variable domain repertoire from canine B cell mRNA using 5'RACE PCR. A set of degenerate primers were then designed and used to clone variable domain genes into archival "holding" plasmid libraries. These archived variable domain genes were then combinatorially ligated to produce a scFv M13 phage library. Next-generation long-read and short-read DNA sequencing methodologies were developed to annotate features of the cloned library including CDR diversity and IGHV/IGKV/IGLV subfamily distribution. A synthetic immunoglobulin G was developed from this scFv library to the canine immune checkpoint receptor PD-1. This synthetic platform can be used to clone and annotate archived antibody variable domain genes for use in perpetuity in order to develop improved preclinical models for the treatment of complex human diseases.
Collapse
Affiliation(s)
- Małgorzata Lisowska
- International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
| | - Erin G Worrall
- University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK
| | - Filip Zavadil-Kokas
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Keith Charlton
- University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK
| | - Euan Murray
- University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK; Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis, Paris, France
| | - M Aiman Mohtar
- University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK
| | - Radovan Krejcir
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Vaclav Hrabal
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Jack Brydon
- University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK
| | | | - David G Saliba
- Faculty of Health Sciences/Department Applied Biomedical Science, Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta
| | - Mariana Grima
- Faculty of Health Sciences/Department Applied Biomedical Science, Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta
| | - Umesh Kalathiya
- International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland
| | - Petr Muller
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Adam Krejci
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - Borivoj Vojtesek
- Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Laboratory of Growth Regulators, Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czech Republic
| | - Kathryn L Ball
- University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK
| | - Robin Fahraeus
- Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St Louis, Paris, France
| | - David J Argyle
- The University of Edinburgh, Royal (Dick) School of Veterinary Studies and Roslin Institute, Edinburgh, UK
| | - Maciej Parys
- The University of Edinburgh, Royal (Dick) School of Veterinary Studies and Roslin Institute, Edinburgh, UK
| | - Ted R Hupp
- International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland; University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, Scotland, UK
| |
Collapse
|
2
|
Liu Y, Lu X, Chen M, Wei Z, Peng G, Yang J, Tang C, Yu P. Advances in screening, synthesis, modification, and biomedical applications of peptides and peptide aptamers. Biofactors 2024; 50:33-57. [PMID: 37646383 DOI: 10.1002/biof.2001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 08/04/2023] [Indexed: 09/01/2023]
Abstract
Peptides and peptide aptamers have emerged as promising molecules for a wide range of biomedical applications due to their unique properties and versatile functionalities. The screening strategies for identifying peptides and peptide aptamers with desired properties are discussed, including high-throughput screening, display screening technology, and in silico design approaches. The synthesis methods for the efficient production of peptides and peptide aptamers, such as solid-phase peptide synthesis and biosynthesis technology, are described, along with their advantages and limitations. Moreover, various modification techniques are explored to enhance the stability, specificity, and pharmacokinetic properties of peptides and peptide aptamers. This includes chemical modifications, enzymatic modifications, biomodifications, genetic engineering modifications, and physical modifications. Furthermore, the review highlights the diverse biomedical applications of peptides and peptide aptamers, including targeted drug delivery, diagnostics, and therapeutic. This review provides valuable insights into the advancements in screening, synthesis, modification, and biomedical applications of peptides and peptide aptamers. A comprehensive understanding of these aspects will aid researchers in the development of novel peptide-based therapeutics and diagnostic tools for various biomedical challenges.
Collapse
Affiliation(s)
- Yijie Liu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Xiaoling Lu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Meilun Chen
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Zheng Wei
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Guangnan Peng
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Jie Yang
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Chunhua Tang
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| | - Peng Yu
- Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
| |
Collapse
|